Gene Logic Recruits Pharmaceutical Executive as Senior Vice President of Clinical Development

  
    
  
  
    
      Gene Logic Inc. (NASDAQ:GLGC) announced today the appointment of Stephen 
      R. Donahue, M.D. as Senior Vice President of Clinical Development. Dr. 
      Donahue will lead the Company’s efforts in 
      clinical development to advance proprietary drug candidates it acquires 
      through drug repositioning partnerships. Dr. Donahue’s 
      responsibilities will integrate with those of Gene Logic’s 
      Rediscovery and Business Development and Licensing groups to drive the 
      growth of the Company’s emerging business in 
      Drug Repositioning.
    
    
      Dr. Donahue’s background includes all phases 
      of clinical drug development and regulatory affairs. He holds board 
      certifications in both Internal Medicine and Clinical Pharmacology. 
      Prior to his appointment at Gene Logic, Dr. Donahue was Vice President, 
      Clinical Research and Operations, at Epix Pharmaceuticals, Inc., a 
      Massachusetts-based, clinical-stage biopharmaceutical company. Before 
      Epix, Dr. Donahue served with Merck & Co., Inc. as Medical Director, 
      Clinical Research, Atherosclerosis and Metabolism. Prior to Merck, he 
      held positions of increasing responsibility with Bristol-Myers Squibb, 
      including in the departments of Clinical Design and Evaluation, and 
      Clinical Pharmacology/Experimental Medicine. He has developed drugs in 
      several different therapeutic areas and has worked on products such as 
      Vytorin®, Pravachol®, 
      and Glucophage®. Dr. Donahue holds an M.D. 
      from Georgetown University, and was an NIH Fellow in Clinical 
      Pharmacology at Georgetown University Medical Center.
    
    
      Charles L. Dimmler, III, Gene Logic Chief Executive Officer and 
      President, said, “Gene Logic’s 
      drug repositioning efforts are proceeding on plan with more than 70 
      compounds under evaluation. An initiative is underway now to secure a 
      development partner for the Company’s first 
      proprietary drug candidate, GL1001, acquired from Millennium 
      Pharmaceuticals. Stephen Donahue has proven expertise in clinical 
      development and will be a key figure as we continue to execute Gene Logic’s 
      strategic plan.”
    
    
      Stephen R. Donahue, M.D., Senior Vice President, Clinical Development 
      for Gene Logic, said, “I’m 
      pleased to be joining Gene Logic at a time when the Company’s 
      Drug Repositioning Program and partnerships with Pfizer, Roche, Abbott, 
      Eli Lilly, Organon, and Lundbeck offer exciting opportunities for 
      clinical development of novel drug candidates in a variety of 
      therapeutic areas. I look forward to applying my clinical development 
      expertise to the development of GL1001 and future Gene Logic drug 
      candidates.”
    
    
      VYTORIN® is a registered trademark of MSP 
      Singapore Company, LLC.
    
    
      PRAVACHOL® and GLUCOPHAGE® 
      are registered trademarks of Bristol-Myers Squibb Company or one of its 
      divisions or subsidiaries.
    
    
      Gene Logic Overview
    
    
      Gene Logic is transforming into a pharmaceutical development company 
      through partnerships with pharmaceutical companies. Our partners provide 
      Gene Logic with access to their drug candidates that have been assessed 
      as safe in human clinical trials but discontinued for other reasons. 
      Gene Logic applies its drug indication platform to find new therapeutic 
      uses for the drug candidates. Gene Logic expects to receive milestone 
      payments and royalties on drug candidates that our partners choose to 
      develop based on the indications we find or, if the partner elects not 
      to pursue such new indications, Gene Logic may receive ownership and 
      development rights.
    
    
      Gene Logic has also developed proprietary genomics databases and 
      services to enable customers worldwide to discover and prioritize drug 
      targets, identify biomarkers, predict toxicity and understand mechanisms 
      of toxicity, and obtain insights into the efficacy of specific 
      compounds. We continue to offer customers these services and licenses to 
      the databases. Such databases, services and expertise are also a vital 
      part of our drug indication platform. Following consideration of various 
      strategic alternatives for its Genomics Division, the Company is 
      concentrating its efforts on investigating the possibility of a sale of 
      all or parts of its Genomics business while continuing to serve new and 
      existing Genomics customers.
    
    
      Founded in 1994, Gene Logic is headquartered in Gaithersburg, Md., with 
      additional research and development facilities in Cambridge, Mass. The 
      Company currently has about 150 employees worldwide. For more 
      information, visit www.genelogic.com 
      or call toll-free – 1/800/GENELOGIC.